Hepatotoxicity Reported With Natalizumab Treatment

The letter is available at: www.fda.gov/medwatch/safety/2008/safety08.htm#Tysabri. Serious adverse events in natalizumab users should be reported to Biogen Idec at 800-456-2255, or to the FSA at www.fda.gov/medwatch.